Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-09-30
Study Completion Date
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Platelets play a major role in thrombus formation and platelet size, measured by Mean Platelet Volume (MPV) correlates with platelet activity. MPV is increased in patients with Myocardial Infarction (MI) and is an independent predictor of adverse events in patients with ST Elevation Myocardial Infarction (STEMI) . Data on MPV in patients with stable angina is limited.
Aspirin and clopidogrel are antiplatelet agents administered routinely to patients undergoing PCI and are required for stent patency. MPV is not known to be affected by low dose Aspirin. Treatment with clopidogrel is thought to reduce MPV in-vitro but the magnitude of this reduction in MPV is unclear, especially in patients with stable angina undergoing PCI. An inverse correlation also exists between MPV and platelet count .
The investigators aim to assess if a change occurs in MPV (∆ MPV) after routine clopidogrel administration in patients with stable angina undergoing PCI.
Aspirin and clopidogrel are antiplatelet agents administered routinely to patients undergoing PCI and are required for stent patency. MPV is not known to be affected by low dose Aspirin. Treatment with clopidogrel is thought to reduce MPV in-vitro but the magnitude of this reduction in MPV is unclear, especially in patients with stable angina undergoing PCI. An inverse correlation also exists between MPV and platelet count .
The investigators aim to assess if a change occurs in MPV (∆ MPV) after routine clopidogrel administration in patients with stable angina undergoing PCI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
NCT01335048
Stable Angina
COMPLETED
PHASE4
Evaluation and Comparison of Several Point-of-care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI.
NCT00352014
Stable Angina Pectoris
COMPLETED
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01505790
Acute Coronary Syndromes
COMPLETED
PHASE3
Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis
NCT07169513
Peripheral Arterial Disease
Silent Atherosclerosis
NOT_YET_RECRUITING
NA
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
NCT02469740
Myocardial Ischemia
Coronary Artery Disease
Endothelial Dysfunction
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, observational study. The investigators aim to conduct this pilot study to assess if there is a change in MPV (∆ MPV) after routine clopidogrel in patients with stable angina undergoing PCI.
Reduced responsiveness to clopidogrel (otherwise known as clopidogrel resistance) is well documented. Clopidogrel resistance can result in adverse long term effects including stent thrombosis and mortality. Diagnosis of clopidogrel resistance requires special analyzers and reagents . There are potential cost factors involved with the analyzers and reagents used for testing resistance. There are no known clinical or biochemical markers of clopidogrel resistance.
If our pilot study results demonstrate that MPV does change (∆MPV) after clopidogrel, then a prospective trial can be conducted in future to correlate ∆MPV with clopidogrel resistance measured by analyzer tests. This could establish ∆MPV as a potential cheap, effective biochemical marker for clopidogrel resistance.
If the investigators are successful in demonstrating a change in MPV with clopidogrel, our pilot study will facilitate conducting future larger studies to demonstrate correlation between ∆MPV and clopidogrel resistance. This could establish ∆MPV as a potential cheap, effective biochemical marker for clopidogrel resistance with resultant benefit to subjects and the institution.
All clopidogrel naive patients with stable angina symptoms who are electively listed for coronary angiography and PCI at Peter Munk Cardiac Centre (PMCC), Toronto General Hospital (TGH), will be included in this pilot study. This pilot study will be conducted in compliance with the protocol, Good Clinical Practice (GCP) and University Health Network (UHN) policy
Study hypothesis. The investigators hypothesize that MPV values remain the same after clopidogrel in patients with stable angina undergoing PCI and aim to disprove the hypothesis
Study Design This prospective pilot study will include consecutive clopidogrel naïve patients with stable angina symptoms, who are electively listed for coronary angiography and PCI at Peter Munk Cardiac Centre (PMCC), Toronto General Hospital (TGH), will be prospectively included in this pilot study. These patients are given a routine loading dose of clopidogrel 600milligrams (mg) followed by a daily dose of clopidogrel 75mg daily after they undergo PCI (as per protocol for all patients who undergo PCI). Complete Blood Count (CBC) is performed routinely in patients prior to the loading dose of clopidogrel (day 0) and on one occasion post PCI as per UHN standard of care. MPV and platelet count are automatically generated during analysis of CBC.
Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days12. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
The samples will be analyzed within 2 hours of venipuncture to minimize artefactual increase in MPV with prolonged exposure to EDTA in the collection tubes .
Change in MPV (∆MPV) and change in platelet count (∆Platelet count) will be calculated as follows:
* MPV = MPV on admission - Mean MPV after clopidogrel
* Platelet count = Platelet count on admission - Mean Platelet count after clopidogrel These results will be correlated with adverse events (readmission and MI) at 30 days by collecting data regarding readmission and cardiac blood tests (for MI) from the electronic patient record (EPR) system online. The universal definition of MI will be adhered to .
Platelet inhibition occurs within 2 hours of a loading dose but reaches a steady state from 3 to 7 days. Repeated samples will ensure the effect of a steady level of clopidogrel on MPV and reduce bias.No change in intervention or medication will occur-all patients will receive treatment according to the UHN standard of care. No randomization or blinding is involved in this pilot study.
The expected duration of participation will be up to 1 month after the index procedure as repeat blood tests are required at day 7 and day 30 after the procedure and adverse events are assessed at day 30.
Patients discharged on the day of the procedure need to return for blood tests the following day, on day 7 and day 30 after the PCI (3 visits). Patients discharged on the day after the procedure will need to return for blood tests on day 7 and day 30 after the PCI (2 visits).
This will involve travel time (approximately 1 hour each way) and time to give the blood sample (30 minutes inclusive of waiting time) equal to a total of 2.5 hours for each visit. Patients will have an overall time commitment of 7.5 hours for 3 visits or 5 hours for 2 visits.
Statistics MPV is automatically analyzed (on a CBC sample) by the Abbott CELL-DYN Sapphire@ analyzer at the TGH laboratory.
The sample size was estimated using the formula:
Z = 1.96 for 95% Confidence Interval (CI) σ = standard deviation (SD) of the outcome variable = 0.219 fl for MPV (Hematology Laboratory Quality Control (QC) for MPV analyzed by Abbott CELL-DYN Sapphire@ (8.46 fl). E (5%) = desired margin of error
In order to ensure that the 95% confidence interval estimate of the MPV in adults with stable angina undergoing PCI is within 0.219 femtolitre (fl) of the true mean MPV, a sample size of 74 patients is required for this pilot project.
Assuming an attrition rate of 30%, a sample size of 100 patients would be required. The formula has taken into account the QC mean obtained for the Abbott CELL-DYN Sapphire@. An attrition rate of 30% was taken into account for patients who may not be able to return for the repeat blood tests.
In addition to determining if MPV changes after clopidogrel or not, ∆MPV will be correlated with the presence of clopidogrel using Receiver Operating Curves (ROC) as will ∆Platelet count. The study will be terminated on completion of collection of 4 blood samples at pre-specified time points in 74 patients (actual calculated sample size) with stable angina undergoing angiography and PCI.
All eligible patients (as per the inclusion criteria) will be included in the trial.
Only persons involved in this pilot study (i.e. PI, Co-PI, research fellows and research nurse) will have access to the source data and documents which will be maintained in a secure location at the PMCC site. Any electronic data will be on specific UHN designated on-site computers, password protected and only accessible to the designated research team.
Review and Assessment of adverse events Adverse effects are not expected at the time of blood collection. A designated contact telephone number for the research nurse will be made available to the participating patients in the event of rare adverse effects such as fainting at the time of blood collection, bruising or infection at the access site.
Consent process Patients will be consented prior to the procedure - the background of the proposed study and the relative benefits and risks of the study will be clearly explained to the patient prior to the procedure on the day. If the patient's native language is not English or the patient does not speak/understand English, then a UHN designated native language translator will be involved for purposes of consent. Patients must sign the consent form prior to enrollment. A UHN prototype consent form prototype will be used for this purpose.
Co-ordinated Approval Process for Clinical Research (CAPCR) form has been submitted for and approved by the Research Ethics Board (REB)
Financing: Funding will be obtained (internally) from the Cardiology Division, PMCC, TGH.
Reduced responsiveness to clopidogrel (otherwise known as clopidogrel resistance) is well documented. Clopidogrel resistance can result in adverse long term effects including stent thrombosis and mortality. Diagnosis of clopidogrel resistance requires special analyzers and reagents . There are potential cost factors involved with the analyzers and reagents used for testing resistance. There are no known clinical or biochemical markers of clopidogrel resistance.
If our pilot study results demonstrate that MPV does change (∆MPV) after clopidogrel, then a prospective trial can be conducted in future to correlate ∆MPV with clopidogrel resistance measured by analyzer tests. This could establish ∆MPV as a potential cheap, effective biochemical marker for clopidogrel resistance.
If the investigators are successful in demonstrating a change in MPV with clopidogrel, our pilot study will facilitate conducting future larger studies to demonstrate correlation between ∆MPV and clopidogrel resistance. This could establish ∆MPV as a potential cheap, effective biochemical marker for clopidogrel resistance with resultant benefit to subjects and the institution.
All clopidogrel naive patients with stable angina symptoms who are electively listed for coronary angiography and PCI at Peter Munk Cardiac Centre (PMCC), Toronto General Hospital (TGH), will be included in this pilot study. This pilot study will be conducted in compliance with the protocol, Good Clinical Practice (GCP) and University Health Network (UHN) policy
Study hypothesis. The investigators hypothesize that MPV values remain the same after clopidogrel in patients with stable angina undergoing PCI and aim to disprove the hypothesis
Study Design This prospective pilot study will include consecutive clopidogrel naïve patients with stable angina symptoms, who are electively listed for coronary angiography and PCI at Peter Munk Cardiac Centre (PMCC), Toronto General Hospital (TGH), will be prospectively included in this pilot study. These patients are given a routine loading dose of clopidogrel 600milligrams (mg) followed by a daily dose of clopidogrel 75mg daily after they undergo PCI (as per protocol for all patients who undergo PCI). Complete Blood Count (CBC) is performed routinely in patients prior to the loading dose of clopidogrel (day 0) and on one occasion post PCI as per UHN standard of care. MPV and platelet count are automatically generated during analysis of CBC.
Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days12. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
The samples will be analyzed within 2 hours of venipuncture to minimize artefactual increase in MPV with prolonged exposure to EDTA in the collection tubes .
Change in MPV (∆MPV) and change in platelet count (∆Platelet count) will be calculated as follows:
* MPV = MPV on admission - Mean MPV after clopidogrel
* Platelet count = Platelet count on admission - Mean Platelet count after clopidogrel These results will be correlated with adverse events (readmission and MI) at 30 days by collecting data regarding readmission and cardiac blood tests (for MI) from the electronic patient record (EPR) system online. The universal definition of MI will be adhered to .
Platelet inhibition occurs within 2 hours of a loading dose but reaches a steady state from 3 to 7 days. Repeated samples will ensure the effect of a steady level of clopidogrel on MPV and reduce bias.No change in intervention or medication will occur-all patients will receive treatment according to the UHN standard of care. No randomization or blinding is involved in this pilot study.
The expected duration of participation will be up to 1 month after the index procedure as repeat blood tests are required at day 7 and day 30 after the procedure and adverse events are assessed at day 30.
Patients discharged on the day of the procedure need to return for blood tests the following day, on day 7 and day 30 after the PCI (3 visits). Patients discharged on the day after the procedure will need to return for blood tests on day 7 and day 30 after the PCI (2 visits).
This will involve travel time (approximately 1 hour each way) and time to give the blood sample (30 minutes inclusive of waiting time) equal to a total of 2.5 hours for each visit. Patients will have an overall time commitment of 7.5 hours for 3 visits or 5 hours for 2 visits.
Statistics MPV is automatically analyzed (on a CBC sample) by the Abbott CELL-DYN Sapphire@ analyzer at the TGH laboratory.
The sample size was estimated using the formula:
Z = 1.96 for 95% Confidence Interval (CI) σ = standard deviation (SD) of the outcome variable = 0.219 fl for MPV (Hematology Laboratory Quality Control (QC) for MPV analyzed by Abbott CELL-DYN Sapphire@ (8.46 fl). E (5%) = desired margin of error
In order to ensure that the 95% confidence interval estimate of the MPV in adults with stable angina undergoing PCI is within 0.219 femtolitre (fl) of the true mean MPV, a sample size of 74 patients is required for this pilot project.
Assuming an attrition rate of 30%, a sample size of 100 patients would be required. The formula has taken into account the QC mean obtained for the Abbott CELL-DYN Sapphire@. An attrition rate of 30% was taken into account for patients who may not be able to return for the repeat blood tests.
In addition to determining if MPV changes after clopidogrel or not, ∆MPV will be correlated with the presence of clopidogrel using Receiver Operating Curves (ROC) as will ∆Platelet count. The study will be terminated on completion of collection of 4 blood samples at pre-specified time points in 74 patients (actual calculated sample size) with stable angina undergoing angiography and PCI.
All eligible patients (as per the inclusion criteria) will be included in the trial.
Only persons involved in this pilot study (i.e. PI, Co-PI, research fellows and research nurse) will have access to the source data and documents which will be maintained in a secure location at the PMCC site. Any electronic data will be on specific UHN designated on-site computers, password protected and only accessible to the designated research team.
Review and Assessment of adverse events Adverse effects are not expected at the time of blood collection. A designated contact telephone number for the research nurse will be made available to the participating patients in the event of rare adverse effects such as fainting at the time of blood collection, bruising or infection at the access site.
Consent process Patients will be consented prior to the procedure - the background of the proposed study and the relative benefits and risks of the study will be clearly explained to the patient prior to the procedure on the day. If the patient's native language is not English or the patient does not speak/understand English, then a UHN designated native language translator will be involved for purposes of consent. Patients must sign the consent form prior to enrollment. A UHN prototype consent form prototype will be used for this purpose.
Co-ordinated Approval Process for Clinical Research (CAPCR) form has been submitted for and approved by the Research Ethics Board (REB)
Financing: Funding will be obtained (internally) from the Cardiology Division, PMCC, TGH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Stable Angina
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mean Platelet Volume
4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
Mean Platelet Volume
Intervention Type
OTHER
Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mean Platelet Volume
Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \> 18 years old
* Able to attend for follow up blood tests
* Able to provide written informed consent
* Able to attend for follow up blood tests
* Able to provide written informed consent
Exclusion Criteria
* \<18 years of age
* Unable to attend for follow up blood tests on days 1, 7 and 30
* Already on clopidogrel at least 1 day prior to presenting for angiography/PCI
* Those who undergo only diagnostic angiography
* History of Myocardial Infarction (MI) in last 1 year
* Anemia (Hb\<100)
* Abnormal (low or high out of range) platelet counts
* Diabetes Mellitus
* Known liver disease
* Known severe renal impairment (eGFR \<30ml/min/1.73m2)
* Known pregnancy
* On Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or steroids
* Known connective tissue disease
* Acute ongoing infections or bleeding
* On oral anticoagulant treatment in the last 1 week
* Pro-coagulant blood disorder
* Known immunosuppressed states
* Treatment with GpIIb/IIIa inhibitor in the last week prior to presentation
* Patients involved in other trials
* Unable to attend for follow up blood tests on days 1, 7 and 30
* Already on clopidogrel at least 1 day prior to presenting for angiography/PCI
* Those who undergo only diagnostic angiography
* History of Myocardial Infarction (MI) in last 1 year
* Anemia (Hb\<100)
* Abnormal (low or high out of range) platelet counts
* Diabetes Mellitus
* Known liver disease
* Known severe renal impairment (eGFR \<30ml/min/1.73m2)
* Known pregnancy
* On Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or steroids
* Known connective tissue disease
* Acute ongoing infections or bleeding
* On oral anticoagulant treatment in the last 1 week
* Pro-coagulant blood disorder
* Known immunosuppressed states
* Treatment with GpIIb/IIIa inhibitor in the last week prior to presentation
* Patients involved in other trials
Minimum Eligible Age
19 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vladimir Dzavik, MD,FRCPC
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Martin JF, Shaw T, Heggie J, Penington DG. Measurement of the density of human platelets and its relationship to volume. Br J Haematol. 1983 Jul;54(3):337-52. doi: 10.1111/j.1365-2141.1983.tb02109.x.
Reference Type
BACKGROUND
Pizzulli L, Yang A, Martin JF, Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J. 1998 Jan;19(1):80-4. doi: 10.1053/euhj.1997.0747.
Reference Type
BACKGROUND
Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, Wilczynska J, Zielinski A, Meier B, Opolski G. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005 Jul 19;46(2):284-90. doi: 10.1016/j.jacc.2005.03.065.
Reference Type
BACKGROUND
Jagroop IA, Mikhailidis DP. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2003 Jan;120(1):169-70. doi: 10.1046/j.1365-2141.2003.03983_4.x. No abstract available.
Reference Type
BACKGROUND
Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS. Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets. 2014;25(3):188-92. doi: 10.3109/09537104.2013.793794. Epub 2013 Jun 20.
Reference Type
BACKGROUND
Goncalves SC, Labinaz M, Le May M, Glover C, Froeschl M, Marquis JF, O'Brien E, Shukla D, Ruchin P, Sookur D, Ha A, So D. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol. 2011 Jan 15;107(2):204-9. doi: 10.1016/j.amjcard.2010.08.068. Epub 2010 Dec 2.
Reference Type
BACKGROUND
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58. doi: 10.2174/138161211795049804.
Reference Type
BACKGROUND
Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981 Sep;76(3):289-93. doi: 10.1093/ajcp/76.3.289.
Reference Type
BACKGROUND
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007 Aug;154(2):221-31. doi: 10.1016/j.ahj.2007.04.014.
Reference Type
BACKGROUND
Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 Jun 17;107(23):2908-13. doi: 10.1161/01.CIR.0000072771.11429.83. Epub 2003 Jun 9.
Reference Type
BACKGROUND
Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 Jun 29;109(25):3171-5. doi: 10.1161/01.CIR.0000130846.46168.03. Epub 2004 Jun 7.
Reference Type
BACKGROUND
Bautista AP, Buckler PW, Towler HM, Dawson AA, Bennett B. Measurement of platelet life-span in normal subjects and patients with myeloproliferative disease with indium oxine labelled platelets. Br J Haematol. 1984 Dec;58(4):679-87. doi: 10.1111/j.1365-2141.1984.tb06115.x.
Reference Type
BACKGROUND
Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002 May;117(2):399-404. doi: 10.1046/j.1365-2141.2002.03441.x.
Reference Type
BACKGROUND
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012 Oct 16;126(16):2020-35. doi: 10.1161/CIR.0b013e31826e1058. Epub 2012 Aug 24. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-8707
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination
NCT01663038
COMPLETED
PHASE1
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
NCT00714961
COMPLETED
PHASE3
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
NCT01779401
COMPLETED
NA
A Prospective muLticEnter Registry in chrONic coronARy synDrOme
NCT06198673
NOT_YET_RECRUITING
Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01339026
TERMINATED
PHASE4
Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.
NCT00262561
COMPLETED
PHASE4
Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.
NCT01011257
WITHDRAWN
PHASE4
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
NCT01496261
COMPLETED
PHASE1
Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting
NCT05559918
RECRUITING
Platelet Function Assessment for Atherothrombotic Patients
NCT00513149
UNKNOWN
PHASE4
Effect of Clopidogrel Loading and Risk of PCI
NCT00457236
UNKNOWN
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
NCT01582217
COMPLETED
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
NCT00335452
COMPLETED
PHASE3
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
NCT01823185
UNKNOWN
PHASE4
Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity
NCT00638326
TERMINATED
PHASE3
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
NCT03431142
COMPLETED
PHASE4
Platelets Induced Vasodilation, in Vitro and in Vivo Study
NCT00152646
UNKNOWN
PHASE4
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
NCT04822363
COMPLETED
EARLY_PHASE1
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
NCT00728156
COMPLETED
PHASE4
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
NCT01465828
COMPLETED
PHASE3
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
NCT00693069
COMPLETED
PHASE3
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
NCT02217501
COMPLETED
PHASE3
Clopidogrel Monotherapy in Patients With High Bleeding Risk
NCT05223335
COMPLETED
PHASE4
Targeting Platelets in Chronic HIV Infection
NCT02578706
COMPLETED
PHASE2
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
NCT00774475
UNKNOWN
PHASE3